Epstein Secrets

Impax Laboratories (IPXL), Kythera Biopharmaceuticals (KYTED, Mallinckrodt (MNK), Merck & Co., Inc. (MRK), Mylan Inc. (MYL), Perris° Company (PRGO), Pfizer Inc. (PFE), Sagent Pharmaceuticals (SGNT), Teva Pharmaceuticals (TEVA), Valeant Pharmaceuticals (VRX), Zoetis (ZTS) M. Morgan Equity Research Ratings Di

J.P.Morgan North America Equity Research O2 June 2014 • Merck & Co., Inc. Pushing Ahead Aggressively in PD-1 Development We attended Merck's ASCO analyst meeting today where the company reviewed new data and development plans for its PD-1 (pembrolizumab). Overall, we increasingly see M

41-6. Public Companies Mentioned in this Report: Astellas Pharma (ALPMY — NR - $15.00) Eli Lilly (LLY — NR - $78.60) Merck & Co (MRK -NR-$54.54) Pfizer Inc. (PFE -NR-$36.13) Johnson & Johnson. (JNJ -NR-$130.41) 24 EFTA00810599 BROOKLINE CAPITAL MARKETS A Division of CIM Securities Veru, Inc. (VEIV

r pulmonary arterial hypertension (PAH). The FDA approved Cialis for treating BPH in 2011. Finasteride (brand names: Proscar. Propecia) marketed by Merck is approved for treatment of enlarged prostate (>30 cc volume) as well as hair loss. Tadalafil can be used in combination with Finasteride can be u

d Chief Executive Officer Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Accel Partners Center for China in the World Economy (CCWE) The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne

Secretary-General Chief Executive Officer Chief Executive Officer Managing Director, Legal and Risk Professor of Management Practice President, Merck Vaccines Director, Center for Public Leadership Artistic and General Director Managing Partner, Strategy and Business Development Managing Direc

Harvard Business School Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Center for China in the World Economy (CCWE) Accel Partners The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne

and Risk Credit Suisse USA William W. George Professor of Management Practice Harvard Business School USA Julie Louise Gerberding President, Merck Vaccines Merck & Co. Inc. USA David R. Gergen Director, Center for Public Leadership Harvard Kennedy School USA Valery Gergiev Artistic and G

Harvard Business School Desjardins Group The Boston Consulting Group Lloyd's Yale University DareDevil Strategies Amobee Publicis Groupe SA Pfizer Inc. Center for China in the World Economy (CCWE) Accel Partners The George Institute for Global Health Balderton Capital thesystemis Bloomberg Ne

and Risk Credit Suisse USA William W. George Professor of Management Practice Harvard Business School USA Julie Louise Gerberding President, Merck Vaccines Merck & Co. Inc. USA David R. Gergen Director, Center for Public Leadership Harvard Kennedy School USA Valery Gergiev Artistic and G

Impax Laboratories (IPXL), Kythera Biopharmaceuticals (KYTH), Mallinckrodt (MNK), Merck & Co., Inc. (MRK), Mylan Inc. (MYL), Perrigo Company (PRGO), Pfizer Inc. (PFE), Sagent Pharmaceuticals (SGNT), Teva Pharmaceuticals (TEVA), Valeant Pharmaceuticals (VRX), Zoetis (ZTS) M. Morgan Equity Research Ratings Di

truda label further reinforces our view that Opdivo will maintain a clear leadership position in the NSCLC marketplace. Overall, we continue to see Merck as a competitive I/O player with a lead in multiple tumors with large unmet need such as HNSCC and colorectal tumors harboring MMR mutations. • Ke